AnaBios Corporation

AnaBios Corporation

AnaBios Corporation is a biotechnology and pharmaceutical company based in San Diego, California, founded in 2009. The company's slogan, "Early Human Insights with Industry-Leading Ex Vivo Human Platforms," encapsulates its core focus on generating predictive human data using ex-vivo human platforms derived from donor organs and tissues. This innovative approach allows AnaBios to study human responses to drugs and explore the molecular and functional basis of human physiology.

The company's research primarily targets areas of high, unmet medical need such as cardiac disease, safety, pain, PKD kidney disease, and neurodegeneration. AnaBios collaborates with global Fortune 500 pharmaceutical companies, CRO's, and universities, positioning itself as a crucial player in advancing the pharmaceutical and biotechnology industries.

In its latest funding round, AnaBios Corporation secured a $6.50 million Series C investment on June 07, 2022, with Ampersand Capital Partners as the lead investor. This substantial investment underscores investor confidence in AnaBios's potential and solidifies its position as an influential player in the biotechnology and pharmaceutical sectors.

With its commitment to revolutionizing drug discovery and clinical trial success rates, AnaBios is well-positioned to drive impactful innovations and deliver valuable insights to the healthcare industry.